OPKO narrows Q1 loss on lower interest expense; diagnostics revenue falls 30% post-oncology sale

Filed April 28, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 1, 2025 · ~2 min read

Key Changes

• high

  Diagnostics service revenue fell $30.7M (30%) as the September 2025 oncology business sale removed $25.9M; remaining $4.8M decline reflects lower test volumes and reimbursement rates in continuing operations.

  MD&A: Diagnostics Revenue verify on EDGAR →
• high

  Interest expense dropped $4.6M (30%) to $10.9M, driven by $4.0M lower interest on 2029 Notes following the April 2025 note exchange that retired $159.2M principal.

  MD&A: Interest Expense verify on EDGAR →
• high

  NGENLA royalty revenue rose $1.9M (42%) to $6.4M; company also recognized $1.4M in new Eli Lilly royalties from Mazdutide, a revenue stream not present in the prior year.

  MD&A: Royalty Revenue verify on EDGAR →